Aerosol delivery device selection for spontaneously breathing patients: 2012

Respiratory Care

Volumn 57, Issue 4, 2012, Pages 613-626

  Ari, Arzu ^a   Restrepo, Ruben D ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aerosol; Device selection; Dry powder inhaler; Metereddose inhaler; Nebulizer; Noninvasive ventilation; Patient adherence; Patient education

Indexed keywords

ADVERSE OUTCOME; AEROSOL; BREATHING PATTERN; EVIDENCE BASED MEDICINE; FLOW RATE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INFECTION RISK; MEDICAL DECISION MAKING; METERED DOSE INHALER; NEBULIZER; OUTCOME ASSESSMENT; OXYGEN DELIVERY DEVICE; OXYGEN MASK; OXYGEN THERAPY; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PHYSICIAN ATTITUDE; POWDER INHALER; PRACTICE GUIDELINE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

AEROSOLS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE; PATIENT SELECTION;

EID: 84860499075     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01756     Document Type: Review

References (190)

1. Welch MJ. Nebulization therapy for asthma: a practical guide for the busy pediatrician. Clin Pediatr 2008;47(8):744-756.
2. Everard ML. Guidelines for devices and choices. J Aerosol Med 2001;14(Suppl 1):S59-S64.
3. National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-S138. Erratum in: J Allergy Clin Immunol 2008;121(6): 1330.
4. Devadason SG, Le Souef PN. Age-associated factors influencing the efficacy of various forms of aerosol therapy. J Aerosol Med 2002;15(3):343-345.
5. Pongracic JA. Asthma delivery devices: age-appropriate use. Pediatr Ann 2003;32(1):50-54.
6. Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008;53(6):699-723.
7. Rau JL. Practical problems with aerosol therapy in COPD. Respir Care 2006;51(2):158-172.
8. Everard ML. Aerosol delivery to children. Pediatr Ann 2006;35(9): 630-636.
9. Everard ML. Inhalation therapy for infants. Adv Drug Deliv Rev 2003;55(7):869-878.
10. Everard ML. Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 2004;17(2):186-195.
11. Cole C. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care 2000;45(6):646-651.
12. Brand P. Key issues in inhalation therapy in children. Curr Med Res Opin 2005;50(10):1313-1321.
13. Ahrens RC. The role of the MDI and DPI in pediatric patients: "children are not just miniature adults". Respir Care 2005;50(10): 1323-1328.
14. Ari A, Hess D, Myers TR, Rau JL. A guide to aerosol delivery devices for respiratory therapists 2nd ed. Irving, TX: American Association for Respiratory Care; 2009.
15. Rubin B, Fink J. Aerosol therapy for children. Respir Care Clin N Am 2001;7(2):100-108.
16. Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992;14(3):192-196.
17. Erzinger S, Schueepp KG, Brooks-Wildhaber J, Devadason SG, Wildhaber JH. Facemasks and aerosol delivery in vivo. J Aerosol Med 2007;20(Suppl 1):S78-S83.
18. Nikander K, Berg E, Smaldone GC. Jet nebulizers versus pressurized metered dose inhalers with valved holding chambers: effects of the facemask on aerosol delivery. J Aerosol Med 2007;20(Suppl 1):S46-S55.
19. Lin HL, Restrepo RD, Gardenhire DS, Rau JL. Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care 2007;52(8):1021-1026.
20. Smaldone GC, Sangwan S, Shah A. Facemask design, facial deposition, and delivered dose of nebulized aerosols. J Aerosol Med 2007;20(Suppl 1):S66-S75.
21. Amirav I, Newhouse MT. Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol 2008;43(3):268-274.
22. Amirav I, Newhouse MT. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 2001;108(2):389-394.
23. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med 2005;18(3):354-363.
24. Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447-452.
25. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127(1):335-371.
26. Geller DE. Comparing clinical features of the nebulizer, metereddose inhaler, and dry powder inhaler. Respir Care 2005;50(10): 1313-1321.
27. Cates CJ, Rowe BH, Bara A. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2002(2):CD000052.
28. Parkin P, Saunders N, Diamond S, Winders P, Macarthur C. Randomized trial spacer vs nebulizer for acute asthma. Arch Dis Child 1995;72(3):239-240.
29. Kerem E, Levison H, Schuh S, O'Brodovich H, Reisman J, Bentur L, Canny GJ. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr 1993; 123(2):313-317.
30. Deerojanawong J, Manuvakorn W, Prapphal N, Harnruthakorn C, Sritippavawan S, Samransamruaikit R. Randomized controlled trial of salbutamol aerosol therapy via metered dose inhaler-spacer vs jet nebulizer in young children with wheezing. Pediatr Pulmonol 2005; 39(5):466-472.
31. Ploin D, Chapuis FR, Stamm D, Robert J, David L, Chatelain PG, et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics 2000;106(2 Pt 1):311-317.
32. Vilarinho LC, Cardeal Mendes CM, de Freitas Souza LS. Metereddose inhalers with home-made spacers versus nebulizers to treat moderate wheezing attacks in children. J Pediatr (Rio J) 2003; 79(5):403-412.
33. Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metereddose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med 2003;157(1):76-80.
34. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, et al; European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008;63(1):5-34. Erratum in: Allergy 2008;63(5):630.
35. Voshaar T, App E, Berdel D, Buhl R, Fischer J, Gessler T, et al; Arbeitsgruppe Aerosolmedizin der Deutschen Gessellschaft für Pneumologie. [Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie 2001;55(12):579-586. Article in German.
36. Chapman K, Voshaar T, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev 2005;14(96):117-122.
37. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, et al; European Respiratory Society Task Force On the Use of Nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001;18(1):228-242.
38. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2010;377(9770):1032-1045.
39. Ari A, Fink JB. Guidelines to aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy? Expert Rev Respir Med 2011;5(4):561-572.
40. Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992;67(5):586-591.
41. Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002;47(11):1257-1275.
42. Le Brun PP, de Boer AH, Heijerman HG, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm World Sci 2000; 22(3):75-81.
43. Hess DR. Nebulizers: principles and performance. Respir Care 2000; 45(6):609-622.
44. Kurosaka F, Nishio H. Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma. Allergol Int 2009;58(4):529-535.
45. Dhand R. Aerosol delivery during mechanical ventilation: from basic techniques to new devices. J Aerosol Med Pulm Drug Deliv 2008;21(1):45-60.
46. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47(12):1406-1416.
47. Dolovich MB, Killian D, Wolff RK, Obminski G, Newhouse MT. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing versus quiet breathing. Am Rev Respir Dis 1977;115(3):397-402.
48. Hess DR. The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med 2007;20(Suppl 1):S85-S98.
49. Pollack C, Fleisch K, Dowsey K. Treatment of acute bronchospasm with-adrenergic agonist aerosols delivered by a nasal bilevel positive airway pressure circuit. Ann Emerg Med 1995;26(5):552-557.
50. Nava S, Karakurt S, Rampulla C, Braschi A, Fanfulla F. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med 2001;27(10):1627-1635.
51. Brandao DC, Lima VM, Filho VG, Silva TS, Campos TF, Dean E, de Andrade AD. Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. J Asthma 2009;46(4):356-361.
52. Fauroux B, Itti E, Pigeot J, Isabey D, Meignan M, Ferry G, et al. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am J Respir Crit Care Med 2000;162(6):2265-2271.
53. Chatmongkolchart S, Schettino G, Dillman C, Kacmarek R, Hess D. In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. Crit Care Med 2002;30(11):2515-2519.
54. Branconnier M, Hess D. Albuterol delivery during noninvasive ventilation. Respir Care 2005;50(12):1649-1653.
55. Abdelrahim ME, Plant P, Chrystyn H. In-vitro characterisation of the nebulised dose during non-invasive ventilation. J Pharm Pharmacol 2010;62(8):966-972.
56. Reychler G. Comparison of lung deposition in two types of nebulization: intrapulmonary percussive ventilation vs jet nebulization. Chest 2004;125:502.
57. Reychler G, Wallemacq P, Rodenstein DO, Cumps J, Leal T, Liistro G. Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring. J Aerosol Med 2006;19(2):199-207.
58. Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care 2010;55(12):1671-1679.
59. Kelly H, Keim K, McWilliams B. Comparison of two methods of delivering continuously nebulized albuterol. Ann Pharmacotherapy 2003;37(1):23-26.
60. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993;21(10):1479-1486.
61. Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med 1996;3(11):1019-1024.
62. Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003(4):CD001115.
63. McPeck M, Tandon R, Hughes K, Smaldone GC. Aerosol delivery during continuous nebulization. Chest 1997;111(5):1200-1205.
64. Newman S. Aerosol generators and delivery systems. Respir Care 1991;36(9):939-951.
65. Yilmaz O, Sogut A, Kose U, Sakinci O, Yuksel H. Influence of ambulatory inhaled treatment with different devices on the duration of acute asthma findings in children. J Asthma 2009;46(2):191-193.
66. Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 2005;50(9):1191-1200.
67. Wildhaber JH, Janssens HM, Pierart F, Dore ND, Devadason SG, LeSouëf PN. High-percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000;29(5):389-393.
68. Wildhaber JH, Devadason SG, Hayden MJ, James R, Dufty AP, Fox RA, et al. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol Eur Respir J 1996;9(19):1943-1946.
69. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, LeSouëf PN. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996;51(10): 985-988.
70. Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath actuated device. Respir Med 2003;97(1):12-19.
71. Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, O'Dowd L. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy Asthma Proc 2010;31(1):26-39.
72. Pedersen S, Hansen O, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65(3): 308-310.
73. Amirav I, Newhouse MT. To inhale or not to inhale: is that the question? A simple method of DPI instruction. J Pediatr 2010; 156(2):339-339, e331.
74. Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005;39(5):447-451.
75. Chavez A, McCracken A, Berlinski AB. Effect of face mask dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010;45(3):224-229.
76. Smaldone GC. Assessing new technologies: patient-device interactions and deposition. Respir Care 2005;50(9):1151-1160.
77. Janssens HM, Tiddens HA. Facemasks and aerosol delivery by metered dose inhaler-valved holding chamber in young children: a tight seal makes the difference. J Aerosol Med 2007;20(Suppl 1): S59-S63.
78. Esposito-Festen J, Ates B, van Vliet F, Hop W, Tiddens H. Aerosol delivery to young children by pMDI-spacer: is facemask design important? Pediatr Allergy Immunol 2005;16(4):348-353.
79. Geller DE. Clinical side effects during aerosol therapy: cutaneous and ocular effects. J Aerosol Med 2007;20(Suppl 1):S100-S109.
80. Amirav I, Shakked T, Broday DM, Katoshevski D. Numerical investigation of aerosol deposition at the eyes when using a hood inhaler for infants-a 3D simulation. J Aerosol Med Pulm Drug Deliv 2008;(2):207-214.
81. Kugelman A, Amirav I, Mor F, Riskin A, Bader D. Hood versus mask nebulization in infants with evolving bronchopulmonary dysplasia in the neonatal intensive care unit. J Perinatol 2006;26(1): 31-36.
82. Amirav I, Balanov I, Gorenberg M, Groshar D, Luder AS. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears! Arch Dis Child 2003;88(8):719-723.
83. Amirav I, Oron A, Tal G, Cesar K, Ballin A, Houri S, et al. Aerosol delivery in respiratory syncytial virus bronchiolitis: hood or face mask? J Pediatr 2005;147(5):627-631.
84. Kacmarek RM, Hess DR. The interface between patient and aerosol generator. Respir Care 1991;36(9):952-976.
85. Rau JL. Delivery of aerosolized drugs to neonatal and pediatric patients. Respir Care 1991;36(6):514-542.
86. Pedersen S. Choice of inhalation therapy in pediatrics. Eur Respir Rev 1994;4:85-88.
87. Scalabrin D, Naspitz C. Efficacy and side effects of salbutamol in acute asthma in children: comparison of the oral route and two different nebulizer systems. J Asthma 1993;30(1):51-59.
88. Canny G, Levison H. Childhood asthma: a rational approach to treatment. Ann Allergy 1990;64(5):406-418.
89. LaForce C, Ellis E, Kordansky D, Cocchetto D, Sharp J. Use and acceptance of Ventolin Rotacaps and the Rotohaler in 1235 asthmatic patients. Clin Therapeutics 1993;15(2):321-329.
90. Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005; 50(10):1304-1312.
91. Lyttle B, Hollestelle A. Asthma: assessment and management in a pediatric hospital Can Fam Physician 1993;39:793-798.
92. Spier S, Drblik S, Lamarre A, Lapierre G, Marcotte J, Bourgeois M. A protocol for aerosol therapy in acute hospitalized asthmatics. J Asthma 1992;29(6):401-405.
93. Rubin BK, Fink JB. The delivery of inhaled medication to the young children. Pediatr Clin North Am 2003;50(3):717-731.
94. Fink JB. Inhalers in asthma management: is demonstration the key to compliance? Respir Care 2005;50(5):598-600.
95. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005;50(10):1360-1374.
96. Bendefy I. Home nebulisers in childhood asthma: survey of hospital supervised use. BMJ 1991;302(6786):1180-1181.
97. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010;182(3):298-306.
98. Wexler M, Rhame F, Blumental M, Cameron S, June B, Fish L. Transmission of gram-negative bacilli to asthmatic children via home nebulizers. Ann Allergy 1991;66(3):267-271.
99. Vassal S, Taamma R, Marty N, Sardet A, d'Athis P, Brémont F, et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000; 28(5):347-351.
100. Estivariz C, Bhatti L, Pati R, Jensen B, Arduino MJ, Jernigan D, et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006;130(5):1346-1353.
101. Hamill R, Georghiou P, Koza M, Goepfert P, Zenon G. Respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122(10):762-766.
102. Rau JL, Restrepo RD. Nebulized bronchodilator formulations: unitdose or multi-dose? Respir Care 2003;48(10):926-939.
103. Lemming C, Marciel J, O'Malley C, Hazle L; Cystic Fibrosis Foundation. Stopping the spread of germs. http://www.cff.org/Uploaded Files/LivingWithCF/StayingHealthy/Germs/StoppingTheSpread/Stopping-the-Spread-of-Germs.pdf. Accessed February 1, 2012.
104. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert TA, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132(1):125-131.
105. Hutchinson G, Parker S, Pryor J, Duncan-Skingle F, Hoffman P, Hodson M. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34(3):584-587.
106. Segal-Maurer S, Kalkut G. Environmental control of tuberculosis: continuing controversy. Clin Infect Dis 1994;19(2):299-308.
107. Hui DS, Chow BK, Chu LC, Ng SS, Hall SD, Gin T, Chan MT. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009;135(3):648-654.
108. Simonds A, Hanak A, Chatwin M, Morrell M, Hall A, Parker K. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebulizer treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborn infections. Health Technol Assess 2010; 14(46):131-172.
109. Seitz T, Deitchman S. Health Hazard Evaluation Report: NIOSH Evaluation 1992;90-140. http://www.cdc.gov/niosh/hhe/reports/pdfs/1990-0140-2221.pdf. Accessed February 1, 2012.
110. Dimich-Ward H, Wymer ML, Chan-Yeung M. Respiratory health survey of respiratory therapists. Chest 2004;126(4):1048-1053.
111. Carnathan B, Martin B, Colice G. Second hand (S)-albuterol: RT exposure risk following racemic albuterol (abstract). Respir Care 2001;46(10):1084.
112. Christiani DC, Kern DG. Asthma risk and occupation as a respiratory therapist. Am Rev Respir Dis 1993;148(3):671-674.
113. Cochrane G, Bosley C. Compliance with inhaled therapy in asthma Eur Respir Rev 1994;4:92-94.
114. Guidry GG, Brown WD, Stogner SW, George RB. Incorrect use of metered dose inhalers by medical personnel. Chest 1992;101(1): 31-33.
115. Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 1992;101(2):316-319.
116. Merkus P, van Essen-Zandlilet E, Parievliet E, Borsboom G, Sterk P, Kerrebijn K. Changes of nebulizer output over the years. Eur Respir J 1992;5(4):488-491.
117. Snell N. Adverse reactions to inhaled drugs. Respir Med 1990; 84(5):345-348.
118. Leuppi JD, Schnyder P, Hartmann K, Reinhart WH, Kuhn M. Druginduced bronchospasm: analysis of 187 spontaneously reported cases. Respiration 2001;68(4):345-351.
119. Babu KS, Marshall BG. Drug-induced airway diseases. Clin Chest Med 2004;25(1):113-122.
120. Walia M, Paul L, Satyavani A, Lodha R, Kalaivani M, Kabra SK. Assessment of inhalation technique and determinants of incorrect performance among children with asthma. Pediatr Pulmonol 2006; 41(11):1082-1087.
121. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003;19(5):443-455.
122. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;52(Suppl 2):S31-S44.
123. Ip AY, Niven RW. Prediction and experimental determination of solute output from a Collison nebulizer. J Pharm Sci 1994;83(7): 1047-1051.
124. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health care-associated pneumonia 2003. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep 2004;53(RR-3):1-36.
125. Sly R. Aerosol therapy in children. Respir Care 1991;36(9):994-1007.
126. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005;50(3):367-382.
127. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004;126(4):1134-1137.
128. Berg E, Picard R. In-vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care 54(12):1671-1678, 2009.
129. Phipps P, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990; 97(6):1327-1332.
130. Dolovich M. Clinical aspects of aerosol physics. Respir Care 1991; 36(9):931-938.
131. Mason J, Miller W, Small S. Comparison of aerosol delivery via Circulaire system vs conventional small volume nebulizer. Respir Care 1994;39(12):1157-1161.
132. Agnew J. Characterizing lung aerosol penetration. J Aerosol Med 1991;4:237-249.
133. Restrepo RD, Dickson SK, Rau JL, Gardenhire DS. An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing. Respir Care 2006;51(1):56-61.
134. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996;110(2):498-505.
135. Silverman M. Aerosol therapy in the newborn. Arch Dis Child 1990;65(8):906-908.
136. Salmon B, Wilson N, Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990;65(4): 410-413.
137. Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81(2):163-165.
138. Everard ML. Trying to deliver aerosols to upset children is a thankless task. Arch Dis Child 2000;82(5):428.
139. Janssens HM, van der Wiel EC, Verbraak AF, de Jongste JC, Merkus PJ, Tiddens HA. Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J Aerosol Med 2003;16(4): 395-400.
140. Bowton D, Goldsmith W, Haponik E. Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large, acute-care hospital. Chest 1992;101(2):305-308.
141. Tenholder M, Bryson M, Whitlock W. A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest 1992;101(3):634-637.
142. Orens D, Kester L, Fergus L, Stoller J. Cost impact of metered dose inhalers vs small volume nebulizers in hospitalized patients: the Cleveland Clinic experience. Respir Care 1991;36(10):1099-1104.
143. Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child 1990;65(7):782-785.
144. Osman L, Hyland M. Patient needs and medication styles in COPD. Eur Respir Rev 2005;14(96):89-92.
145. Zainudin B, Biddiscombe M, Tolfree S, Short M, Spiro S. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990;45(6):469-473.
146. Wildhaber JH, Dore ND, Wilson JM, Devadason SG, LeSouëf PN. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999;135(1):28-33.
147. Fok T, Lam K, Ng P, Leung TF, So HK, Cheung KL, Wong W. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Respir J 1998;12(1):159-164.
148. Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. Prim Care Respir J 2007;16(4): 207-214.
149. Janssens H, Heijnen E, de Jong V, Holland W, de Jongste J, Tiddens H. Aerosol delivery from spacers in wheezy infants: a daily life study. Eur Repir J 2000;16(5):850-856.
150. Shah S, Berlinski A, Rubin BK. Force-dependent static dead space of face masks used with holding chambers Respir Care 2006;51(2): 140-144.
151. Hayden J, Smith N, Woolf D, Barry P, O'Callaghan C. A randomised crossover trial of facemask efficacy. Arch Dis Child 2004; 89(1):72-73.
152. Amirav I, Mansour Y, Mandelberg A, Bar-Ilan I, Newhouse M. Redesigned face mask improves "real life" aerosol delivery for Nebuchamber. Pediatr Pulmonol 2004;37(2):172-177.
153. Amirav I. Infant aerosol holding chamber face masks: not all are born equal! Respir Care 2006;51(2):123-125.
154. Janssens H, Tiddens H. Aerosol therapy: the special needs of young children. Pediatr Respir Rev 2006;7(Suppl 1):S83-S85.
155. Rubin BK. Bye-bye, blow-by (editorial). Respir Care 2007;52(8): 981.
156. Lin L, Restrepo RD, Gardenhire DS, Rau JL. Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care 2007;52(8):1021-1026.
157. Vidgren MT. Factors influencing lung deposition of inhaled aerosols. Eur Respir J 1994;4:68-70.
158. Kurosaka F, Nishio H. Comparison of the bronhodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma Allergol Int 2009;58(4):529-535.
159. Dhuper S, Chandra A, Ahmed A, Bista S, Moghekar A, Verma R, et al. Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment. J Emerg Med 2011;40(3): 247-255.
160. Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma. J Pediatr 2000(4):497-502.
161. Turner MO, Gafni A, Swan D, FitzGerald JM. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996;156(18)2113-2118.
162. Jasper A, Monhsenifar Z, Kahan S, Goldberg H, Koerner S. Costbenefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987;91(4):614-618.
163. Dhuper S, Chandra A, Ahmed A, Bista S, Moghekar A, Verma R. Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma in an inner-city adult population. Am J Health Syst Pharm 2008;62(10):1053-1061.
164. Summer W, Elston R, Tharpe L, Nelson S, Haponik EF. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989;149(3): 618-623.
165. Salyer JW, DiBlasi RM, Crotwell DN, Cowan CA, Carter ER. The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. Respir Care 2008;53(3):338-345.
166. Hendeles L, Hatton RC, Coons TJ, Carlson L. Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber. Am J Health Syst Pharm 2005;62(10): 1053-1061.
167. Kim SH, Kwak HJ, Kim TB, Chang YS, Jeong JW, Kim CW, et al. Inappropriate techniques used by internal medicine residents with three kinds of inhalers (a metered dose inhaler, Diskus, and Turbuhaler): changes after a single teaching session. J Asthma 2009; 46(9):944-950.
168. Cunha AJ, Santos MA, Galvão MG, Ibiapina AA. Knowledge of pediatricians in Rio de Janeiro, Brazil about inhalation therapy in asthmatic children. Allergol Immunopathol (Madr) 2003;31(2):87-90.
169. Self TH, Arnold LB, Czosnowski LM, Swanson JM, Swanson H. Inadequate skill of healthcare professionals in using asthma inhalation devices. J Asthma 2007;44(8):593-598.
170. Amirav I, Burg F. The need to educate health professionals about childhood asthma. Arch Pediatr Adolesc Med 1994;148(12):1339-1343.
171. Benjaponpitak S, Kraisarin C, Direkwattanachai C, Sasisakunporn C. Incorrect use of metered dose inhaler by pediatric residents. J Med Assoc Thai 1996;79(2):122-126.
172. Melani AS. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007;78(3):233-245.
173. Lewis RM, Fink JB. Promoting adherence to inhaled therapy: building partnerships through patient education. Respir Care Clin N Am 2001;7(2):277-301.
174. Akapo S, Gupta J, Martinez E, McCrea C, Ye L, Roach M. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother 2008;42(10): 1416-1424.
175. Kamin W, Schwabe A, Kramer I. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5(4):205-213.
176. Burchett D, Darko W, Zahra J, Noviasky J, Probst L, Smith A. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm 2010;67(3):227-230.
177. Hagmolen of ten Have W, van de Berg N, Bindels P, van Aalderen W, van der Palen J. Assessment of inhalation technique in children in general practice:increased risk of incorrect performance with new device. J Asthma 2008;45(1):67-71.
178. Rubin BK. What does it mean when a patient says, "My asthma medication is not working"? Chest 2004;126(3):972-981.
179. Deerojanawong J, Promsakana Sakolnakorn V, Prapphal N, Hanrutakorn C, Sritippayawan S. Evaluation of metered-dose inhaler administration technique among asthmatic children and their caregivers in Thailand. Asian Pac J Allergy Immunol 2009;27(2-3):87-93.
180. Lavorini F, Levy ML, Dekhuijzen PN, Crompton GK. Inhaler choice and inhalation technique: key factors for asthma control. Prim Care Respir J 2009;18(4):241-242.
181. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102(4):593-604.
182. Caldwell N. Nebulization in hospitals and home: standardizing the variables. Eur Respir Rev 1994;4:99-101.
183. Burgess S, Sly P, Devadason S. Providing feedback on adherence increases use of preventive medication by asthmatic children. J Asthma 2010;47(2):198-201.
184. Brand PL, van der Baan-Slootweg OH, Heynens JW, de Vries TW, Versteegh FG, Vreuls RC, et al. Comparison of handling and acceptability of two spacer devices in young children with asthma. Acta Paediatr 2001;90(2):133-136.
185. O'Malley CA, VandenBranden SL, Zheng XT, Polito AM, McColley SA. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care 2007;52(3):258-262.
186. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. AmJ Infect Control 2003;31(3):S6-S62.
187. Centers for Disease Control and Prevention. Guideline for prevention of nosocomial pneumonia. Respir Care 1994;39(12):1191-1236.
188. US Food and Drug Administration. Public Health Advisory: Contamination of multi-dose bottles of albuterol sulfate solution for inhalation (0.5%). April 19, 2002. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety InformationforHeathcareProfessionals/PublicHealthAdvisories/ucm 170883.htm. Accessed February 1, 2012.
189. Guyatt G, Oxman A, Vist Gea. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-926.
190. Jaeschke R, Guyatt G, Dellinger P, Schünemann H, Levy M, Kunz Rea. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744. DOI:10.1136/bmj.a744.